Table of Contents
- Key Points
- Why This Research Matters
- Understanding Atherosclerosis: The Basics
- The Problem of Residual Risk
- How Researchers Study Plaques: New Imaging Methods
- Key Findings: What We Now Know About Plaque Evolution
- What This Means for Patients
- Limitations of This Research
- Recommendations for Patients
- Frequently Asked Questions
- Source Information
Key Points
- Atherosclerosis is the world's leading cause of death and disability, affecting coronary and carotid arteries.
- Residual risk means heart attacks and strokes still occur despite optimal treatment with statins, surgery, and lifestyle changes.
- Advanced imaging (IVUS, OCT, NIRS) can reveal plaque composition, lipid volume, and fibrous cap thickness inside artery walls.
- Dangerous plaques have a thin fibrous cap, large fatty core, and inflammation; they can evolve from stable to unstable over time.
- Patients can shift plaques toward stability by taking statins as prescribed, quitting smoking, exercising, and controlling blood pressure and blood sugar.
Why This Research Matters
Heart disease and stroke remain the world's biggest killers. This review article, published in the journal Molecular and Cellular Biochemistry, tackles a question that has puzzled cardiologists for years: Why do some patients still experience heart attacks and strokes even when they receive the best available treatment?
Researchers Sunil K. Noothi, Mohamed Radwan Ahmed, and Devendra K. Agrawal from the Department of Translational Research at Western University of Health Sciences in Pomona, California, set out to examine this persistent problem. Their goal was to explain the gap between current treatments and perfect outcomes—what doctors call "residual risk."
The authors highlight that atherosclerotic disease (hardening and narrowing of the arteries) of the coronary arteries (which supply blood to the heart) and carotid arteries (which supply blood to the brain) is the primary global cause of significant mortality and morbidity. This means it is the number one reason people around the world die or become seriously ill.
Chronic occlusive diseases—conditions where arteries become progressively blocked over time—have fundamentally changed the health landscape. This shift affects not just wealthy nations but also developing countries, where cardiovascular disease has become an increasingly heavy burden alongside traditional infectious diseases.
Understanding Atherosclerosis: The Basics
Atherosclerosis is a slow, progressive condition in which plaque—a combination of cholesterol, fat, calcium, and inflammatory cells—accumulates inside artery walls. Think of it like rust building up inside a pipe: over time, the opening narrows, and blood flow becomes restricted.
But the story is more complicated than simple narrowing. Over the past two decades, researchers have learned that plaque composition matters more than plaque size. Some plaques are stable—they sit quietly in the artery wall for years without causing trouble. Others are unstable or "vulnerable"—they have thin fibrous caps (the protective covering over the fatty core) that can rupture, triggering a blood clot that blocks the artery entirely.
When such a rupture happens in a coronary artery, the result is a heart attack (sometimes called an acute cardiac event). When it happens in a carotid artery, it can cause a stroke. These are what the authors call major adverse atherothrombotic events—the catastrophic outcomes that doctors are working desperately to prevent.
The Problem of Residual Risk
Over the last four decades, medicine has made enormous progress. The authors acknowledge several key advances:
- Advanced revascularization techniques—procedures like coronary bypass surgery and stent placement that physically reopen blocked arteries
- Widespread use of statins—medications that lower cholesterol and reduce inflammation
- Successful targeting of modifiable risk factors—particularly smoking cessation and increased exercise
Despite all these achievements, the authors point to a sobering reality: there is still a definite "residual risk" in the population.
Every year, many prevalent cases (people living with the disease) and new cases (people newly diagnosed) continue to appear. This persistent risk exists even in patients who take their medications faithfully, adopt healthy lifestyles, and receive state-of-the-art procedures. The residual risk is the gap between what current treatments can achieve and what would be needed to fully eliminate heart attacks and strokes.
This review places special emphasis on strokes and cardiovascular risks, noting that both conditions share the same underlying disease process. If doctors can better understand why plaques evolve and rupture, they might be able to close this gap.
How Researchers Study Plaques: New Imaging Methods
One of the most exciting developments described in this review is the use of advanced imaging technology to look inside arteries. Previously, doctors relied on conventional angiography—an X-ray technique that shows only the silhouette of the artery lumen (the hollow opening where blood flows). While useful for detecting blockages, angiography cannot reveal what is happening inside the artery wall itself.
Three newer techniques are changing that picture:
- Intravascular ultrasound (IVUS)—a tiny ultrasound probe mounted on a catheter (a thin flexible tube) that is threaded into the artery. It uses sound waves to create detailed images of the artery wall from the inside, revealing the size and extent of plaque that angiography cannot see.
- Optical coherence tomography (OCT)—a catheter-based imaging method that uses near-infrared light to produce extremely high-resolution images. OCT provides exceptionally detailed views of the plaque surface, allowing doctors to measure the thickness of the fibrous cap that protects the plaque's fatty core.
- Near-infrared spectroscopy (NIRS)—a technique that shines near-infrared light onto the artery wall and analyzes the reflected spectrum to identify the chemical composition of the plaque. NIRS can detect lipid (fat) content, helping to identify dangerous lipid-rich plaques.
The authors explain that these techniques are being used in clinical settings to achieve surrogate end points—measurable markers that stand in for, and help predict, real patient outcomes like heart attacks and strokes. Since major cardiovascular events are relatively rare in a short time frame, researchers use these imaging markers (such as changes in plaque size or composition) to evaluate how well a treatment is working.
Key Findings: What We Now Know About Plaque Evolution
The review presents a critical discussion of how atherosclerotic plaques evolve in both coronary and carotid arteries. This new understanding has fundamentally changed the scientific community's view of plaque biology.
Changing views on stable vs. unstable plaques
Traditionally, doctors classified plaques as either stable (safe) or unstable (dangerous). The authors explain that this binary view is too simple. Plaques exist on a spectrum and can change over time. A plaque that appears stable today may evolve into a destabilized, high-risk plaque tomorrow—and vice versa. This concept of evolving plaques is central to the review.
The key features that make a plaque dangerous include:
- A thin fibrous cap (the protective layer becomes weakened)
- A large lipid (fatty) core
- Active inflammation within the plaque (inflammatory cells infiltrating the tissue)
- A tendency toward vulnerability—meaning the plaque is prone to rupture
Plaque evolution before a major event
Perhaps the most important insight highlighted by the authors is that plaques do not suddenly rupture without warning. They evolve over time, passing through stages of stability and instability before a major adverse atherothrombotic event occurs. Understanding this evolution is critical because it means there may be a window of opportunity to intervene before a heart attack or stroke happens.
What new imaging reveals
The advanced techniques described above are now providing "exquisite information" that was previously impossible to obtain with conventional angiography. Specifically, doctors can now assess:
- Plaque size—how much of the artery wall is occupied by plaque
- Plaque composition—what the plaque is made of (fat, calcium, fibrous tissue, or a mixture)
- Lipid volume—the amount of fatty material within the plaque, which correlates with danger
- Fibrous cap thickness—the strength of the protective barrier over the fatty core; thinner caps are more likely to rupture
All of these features serve as surrogate end points that help researchers and clinicians identify the most dangerous plaques and monitor how they change over time or in response to treatment.
What This Means for Patients
This research has several direct implications for patients living with—or at risk for—atherosclerotic disease.
Better risk identification
The ability to see plaque composition and fibrous cap thickness means that doctors can potentially identify "vulnerable" plaques before they rupture. Rather than simply asking "how blocked is the artery?" they can now ask "how dangerous is the plaque?" This is a crucial distinction, because many heart attacks occur at sites with only moderate narrowing—the danger comes from the plaque's vulnerability, not its size.
Personalized treatment potential
If a patient is found to have a lipid-rich plaque with a thin fibrous cap, they may benefit from more aggressive cholesterol-lowering therapy or additional anti-inflammatory treatment. Conversely, a patient with a thick-capped, stable plaque might be safely managed with standard care. This moves medicine closer to personalized treatment plans based on each individual's actual plaque profile.
The ongoing challenge of residual risk
For patients, the concept of residual risk serves as an important reminder: even the best medical care cannot eliminate all danger. The authors note that this risk persists "despite advanced management settings," meaning that patients and doctors must remain vigilant even after successful procedures and optimal medical therapy.
Inflammation as a key player
The review highlights inflammation as a central mechanism in plaque evolution. This suggests that future treatments may need to address inflammation directly, not just cholesterol levels. Some anti-inflammatory medications have already been shown to reduce cardiovascular events in clinical trials, and this area of research continues to evolve.
Limitations of This Research
It is important to understand what this review does and does not show. Like all scientific studies, this work has limitations that patients should be aware of:
- This is a review article, not a clinical trial. It summarizes and interprets existing research rather than presenting new patient data. As such, it cannot prove that any specific treatment changes outcomes.
- Surrogate end points are not the same as patient outcomes. While changes in plaque size, lipid volume, and fibrous cap thickness are strongly associated with cardiovascular risk, these imaging markers are not guaranteed to predict whether an individual patient will actually have a heart attack or stroke.
- The imaging techniques described are not universally available. IVUS, OCT, and NIRS are performed in specialized centers and are not part of routine care for all patients with atherosclerosis. They are primarily used in research settings and high-risk cases.
- The article focuses on coronary and carotid arteries. The findings may not apply equally to atherosclerosis in other parts of the body, such as the peripheral arteries in the legs.
Patients should understand that while these findings are promising, they represent an evolving area of science. More research is needed to determine how best to use this new information to improve survival and quality of life.
Recommendations for Patients
Based on the insights from this review, here are practical steps patients can consider. These recommendations align with the "modifiable risk factors" the authors emphasize—things you can actively change:
- Take your statin medication exactly as prescribed. Statins do more than lower cholesterol—they also stabilize plaques, making the fibrous cap thicker and reducing inflammation. Even if your cholesterol numbers look good, the plaque-stabilizing benefits continue.
- Quit smoking, and if you don't smoke, don't start. Smoking damages the endothelium (the lining of arteries), accelerates plaque growth, and promotes inflammation. It is one of the most powerful modifiable risk factors.
- Exercise regularly. Even moderate physical activity improves blood flow, reduces inflammation, and helps stabilize blood pressure and weight. The authors specifically note exercise as a key modifiable factor that has successfully reduced risk over the past four decades.
- Control blood pressure and blood sugar. Hypertension and diabetes are major contributors to plaque progression. Work with your healthcare team to keep these in target ranges.
- Understand your medications. If you have multiple medications, including antiplatelet drugs (like aspirin or clopidogrel) and blood pressure medicines, take them consistently. The "residual risk" concept reminds us that every protective measure counts.
- Have an open conversation with your cardiologist. Ask about your individual risk profile. In certain high-risk situations, newer imaging techniques might help clarify your condition, though they are not appropriate for everyone.
- Stay informed but not alarmed. The concept of evolving plaques means the disease is dynamic. A healthy lifestyle and proper medication can shift plaques toward stability. Your daily choices genuinely influence the character of the plaque inside your arteries.
The authors' emphasis on changing plaque biology offers a message of hope: the disease process is not static, and neither is the treatment strategy. Science is moving toward an era where doctors can not only detect blockages but also assess their biological danger and potentially intervene before a catastrophic event occurs.
Frequently Asked Questions
What is the difference between a stable and a vulnerable (unstable) plaque?
A stable plaque sits quietly in the artery wall for years without causing trouble. A vulnerable plaque has a thin protective cap, a large fatty core, and active inflammation, making it prone to rupture. Rupture can trigger a blood clot that blocks the artery, causing a heart attack or stroke.
How can doctors see plaque inside the artery wall instead of just the narrowing?
New imaging tools such as intravascular ultrasound (IVUS), optical coherence tomography (OCT), and near-infrared spectroscopy (NIRS) look inside the artery wall. IVUS uses sound waves, OCT uses light for high-resolution images, and NIRS detects fat content. These methods reveal plaque size, composition, and fibrous cap thickness, which standard angiography cannot.
What exactly makes a plaque dangerous?
A plaque is dangerous when it has a thin fibrous cap over a large lipid (fatty) core, along with active inflammation inside the plaque. This makes it vulnerable to rupture. Rupture can lead to a blood clot that blocks blood flow, causing a heart attack or stroke.
Can my plaque become less dangerous over time?
Yes. Plaques are not fixed – they evolve on a spectrum between stable and unstable. Taking statins as prescribed, quitting smoking, exercising, and controlling blood pressure and blood sugar can shift plaques toward stability. Statins also thicken the fibrous cap and reduce inflammation, helping to make plaques safer.
What should I ask my cardiologist about my personal risk and plaque vulnerability?
Ask about your individual risk profile, whether your plaque burden or composition is being assessed, and if newer imaging methods like IVUS, OCT, or NIRS are appropriate in your case. Also ask how aggressively to manage cholesterol, blood pressure, and inflammation, and whether all your medications are optimized to reduce residual risk.
Should I get a second opinion if my cardiologist says my plaque is stable but I still worry about residual risk of heart attack or stroke?
Yes, a second opinion can be valuable if you have residual risk despite optimal treatment, because plaque vulnerability—not just narrowing—determines danger. Advanced imaging like IVUS, OCT, or NIRS can reveal fibrous cap thickness and lipid volume, which may change your risk assessment and treatment plan. If your doctor hasn't discussed these options, another expert might. Diagnostic Detectives Network provides independent expert second opinions.
Source Information
Original article: "Residual risks and evolving atherosclerotic plaques"
Authors: Sunil K. Noothi, Mohamed Radwan Ahmed, Devendra K. Agrawal
Affiliation: Department of Translational Research, Western University of Health Sciences, Pomona, California, USA
Journal: Molecular and Cellular Biochemistry, published online March 10, 2023
Publication details: DOI: 10.1007/s11010-023-04689-0 | PMID: 36897542
Keywords from original article: Acute cardiac event; Atherosclerosis; Fibrous cap; Inflammation; Residual risk; Stable plaque; Unstable plaque; Vulnerability
This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace professional medical advice. Always consult your healthcare provider regarding your specific condition and treatment options. This article was written for patients and caregivers to help bridge the gap between complex scientific literature and everyday understanding.
